CASP9 and central nervous system cancer: Utilizing “shORC6-s1” and “shORC6-s2” to knock down ORC6 or employing the CRISPR/Cas9 method to KO ORC6 led to increased caspase-3 (Fig. 5A) and caspase-9 (Fig. 5B) activities within P1 glioma cells.